The U.S. Patent Office has granted CollPlant Ltd a patent covering processing methods for making human collagen from plants. Collagen is the most common protein in the human body. CollPlant’s technology is based on the production of human collagen through the genetic engineering of tobacco plants by implanting five genes in them that are found in the connective tissues of the human body.
Patent Awarded for Plant-Based Collagen
1 min read Premium comments
Secondary
According to its press release, the company is developing a range of solutions that include products to treat the inflammation of tendons, of chronic wounds among diabetic patients and a bone graft substitute for bone healing.
Besides the U.S. Patent Office, countries that have granted patents for CollPlant’s core technology are: the European Union, China, Japan, Australia, South Africa, India, Mexico, New Zealand and Singapore. CollPlant, established in Israel in 2004, is focused on advancing regenerative medicine
Company CEO Yehiel Tal said, “The USA is one of the company’s strategic target markets, and we see the strengthening of our intellectual property in this territory as a significant achievement.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.